Wordt geladen...
Clinical Outcomes of Patient Subgroups in the TANGO II Study
INTRODUCTION: Meropenem–vaborbactam (M-V), a new approved antimicrobial, was developed specifically to be effective treatment for the increasingly prevalent and difficult to treat carbapenem-resistant Enterobacterales (CRE) infections. However, registration phase 3 clinical studies offer limited app...
Bewaard in:
| Gepubliceerd in: | Infect Dis Ther |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Healthcare
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7872113/ https://ncbi.nlm.nih.gov/pubmed/33565042 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40121-021-00405-x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|